How two sites of inflammation promote carcinogenesis: The role of macrophages in inflammation associated carcinogenesis

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 951-953

  Sebens, Susanne ^a   Schäfer, Heiner ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Laboratory of Molecular Gastroenterology and Hepatology   (Germany)

Author keywords

CD171; Colitis associated cancer; Colorectal cancer; Epithelial mesenchymal transition; L1CAM; Macrophages; Nrf2

Indexed keywords

CELL ADHESION MOLECULE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; L1CAM PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER RISK; CARCINOGENESIS; CHRONIC INFLAMMATION; COLITIS; COLON MUCOSA; COLORECTAL CANCER; ENTERITIS; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; INFLAMMATION; MACROPHAGE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84886943659     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19949     Document Type: Article

References (10)

1. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140:1807-16; PMID:21530747; http://dx.doi.org/10.1053/j.gas-tro.2011.01.057.
2. Sebens S, Bauer I, Geismann C, Grage-Griebenow E, Ehlers S, Kruse ML, et al. Inflammatory macro-phages induce Nrf2 transcription factor-dependent proteasome activity in colonic NCM460 cells and thereby confer anti-apoptotic protection. J Biol Chem 2011; 286:40911-21; PMID:21990354; http://dx.doi.org/10.1074/jbc.M111.274902.
3. Stadnicki A, Machnik G, Klimacka-Nawrot E, Wolanska-Karut A, Labuzek K. Transforming growth factor-beta1 and its receptors in patients with ulcer-ative colitis. Int Immunopharmacol 2009; 9:761-6; PMID:19285572; http://dx.doi.org/10.1016/j.intimp.2009.02.014.
4. Schäfer H, Struck B, Feldmann EM, Bergmann F, Grage-Griebenow E, Geismann C, et al. TGFβ1-dependent L1CAM expression has an essential role in macrophage-induced apoptosis resistance and cell migration of human intestinal epithelial cells. Oncogene 2012; Epub ahead of print; PMID:22349829; http://dx.doi.org/10.1038/onc.2012.44.
5. Schäfer H, Geismann C, Heneweer C, Egberts JH, Korniienko O, Kiefel H, et al. Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent. Carcinogenesis 2012; 33:84-93; PMID:22095073; http://dx.doi.org/10.1093/carcin/bgr262.
6. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005; 168:633-42; PMID:15716380; http://dx.doi.org/10.1083/jcb.200408051.
7. Sebens Müerköster S, Werbing V, Sipos B, Debus MA, Witt M, Grossmann M, et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2007; 26:2759-68; PMID:17086212; http://dx.doi.org/10.1038/sj.onc.1210076.
8. Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas E F, et al. L1 is associated with micrometa-static spread and poor outcome in colorectal cancer. Mod Pathol 2007; 20:1183-90; PMID:17873897; http://dx.doi.org/10.1038/modpathol.3800955.
9. Schäfer H, Dieckmann C, Korniienko O, Moldenhauer G, Kiefel H, Salnikov A, et al. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett 2012; 319:66-82; PMID:22210381; http://dx.doi.org/10.1016/j.canlet.2011.12.035
10. Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorec-tal cancer. Cancer Microenviron 2011; 4:141-54; PMID:21909876; http://dx.doi.org/10.1007/s12307-010-0052-5.